Valuation : Sensorion

Market Cap 117M 136M 111M 101M 189M 13.01B 190M 1.32B 508M 6.62B 512M 500M 20.92B P/E 2026 *
-30.4x
P/E 2027 * -5.07x
Enterprise Value -14.64M -17M -13.87M -12.57M -23.58M -1.62B -23.7M -165M -63.33M -826M -63.83M -62.43M -2.61B EV / Sales 2026 *
-0.67x
EV / Sales 2027 * 18.4x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 31/05/2026
Director of Finance/CFO - 25/06/2024
Chief Tech/Sci/R&D Officer - 10/12/2023
Director TitleAgeSince
Director/Board Member - 08/03/2015
Director/Board Member 43 -
Chairman 61 29/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 136M
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.69B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average +0.44%-3.57%+62.86%+104.96% 29.42B
Weighted average by Cap. +0.41%-3.67%+74.58%+124.28%

Financials

2026 *2027 *
Net sales 21.86M 25.37M 20.7M 18.76M 35.19M 2.42B 35.37M 246M 94.53M 1.23B 95.28M 93.19M 3.9B 6.4M 7.42M 6.06M 5.49M 10.3M 709M 10.35M 71.92M 27.66M 361M 27.87M 27.26M 1.14B
Net income -237K -275K -224K -203K -381K -26.24M -383K -2.66M -1.02M -13.35M -1.03M -1.01M -42.19M -36.12M -41.92M -34.2M -31M -58.16M -4.01B -58.45M -406M -156M -2.04B -157M -154M -6.44B
Net Debt -132M -153M -125M -113M -213M -14.64B -214M -1.48B -571M -7.45B -575M -563M -23.53B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2280EUR
Average target price
1.138EUR
Spread / Average Target
+398.90%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!